126 related articles for article (PubMed ID: 35920378)
1. Aberrant OCIAD2 demethylation in lung adenocarcinoma is associated with outcome.
Maki M; JeongMin H; Nakagawa T; Kawai H; Sakamoto N; Sato Y; Noguchi M
Pathol Int; 2022 Oct; 72(10):496-505. PubMed ID: 35920378
[TBL] [Abstract][Full Text] [Related]
2. Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma.
Shiba-Ishii A; Noguchi M
Am J Pathol; 2012 Apr; 180(4):1653-62. PubMed ID: 22310466
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
[TBL] [Abstract][Full Text] [Related]
4. Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma.
Hong J; Shiba-Ishii A; Kim Y; Noguchi M; Sakamoto N
Cancer Sci; 2021 Dec; 112(12):5114-5126. PubMed ID: 34628698
[TBL] [Abstract][Full Text] [Related]
5. Frequent aberrant methylation of the promoter region of sterile alpha motif domain 14 in pulmonary adenocarcinoma.
Sun W; Iijima T; Kano J; Kobayashi H; Li D; Morishita Y; Okubo C; Anami Y; Noguchi M
Cancer Sci; 2008 Nov; 99(11):2177-84. PubMed ID: 18823374
[TBL] [Abstract][Full Text] [Related]
6. OCIA domain containing 2 is highly expressed in adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component and is associated with better prognosis.
Ishiyama T; Kano J; Anami Y; Onuki T; Iijima T; Morisita Y; Yokota J; Noguchi M
Cancer Sci; 2007 Jan; 98(1):50-7. PubMed ID: 17054434
[TBL] [Abstract][Full Text] [Related]
7. OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.
Wu D; Yang X; Peng H; Guo D; Zhao W; Zhao C; Zhou X
Carcinogenesis; 2017 Sep; 38(9):910-919. PubMed ID: 28911005
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
[TBL] [Abstract][Full Text] [Related]
10. Genome-scale meta-analysis of DNA methylation during progression of lung adenocarcinoma.
Zhang QH; Dai XH; Dai ZM; Cai YN
Genet Mol Res; 2015 Aug; 14(3):9200-14. PubMed ID: 26345853
[TBL] [Abstract][Full Text] [Related]
11. Individualized analysis reveals CpG sites with methylation aberrations in almost all lung adenocarcinoma tissues.
Yan H; Guan Q; He J; Lin Y; Zhang J; Li H; Liu H; Gu Y; Guo Z; He F
J Transl Med; 2017 Feb; 15(1):26. PubMed ID: 28178989
[TBL] [Abstract][Full Text] [Related]
12. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.
He D; Zhang YW; Zhang NN; Zhou L; Chen JN; Jiang Y; Shao CK
Med Oncol; 2015 Apr; 32(4):92. PubMed ID: 25720522
[TBL] [Abstract][Full Text] [Related]
13. A functional methylation signature to predict the prognosis of Chinese lung adenocarcinoma based on TCGA.
Wang K; Liu Y; Lu G; Xiao J; Huang J; Lei L; Peng J; Li Y; Wei S
Cancer Med; 2022 Jan; 11(1):281-294. PubMed ID: 34854250
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.
Zhang Y; Xu H; Mu J; Guo S; Ye L; Li D; Peng W; He X; Xiang T
J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
Kim YT; Park SJ; Lee SH; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1378. PubMed ID: 16256792
[TBL] [Abstract][Full Text] [Related]
16. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines.
Yanagawa N; Tamura G; Honda T; Endoh M; Nishizuka S; Motoyama T
Clin Cancer Res; 2004 Apr; 10(7):2447-51. PubMed ID: 15073123
[TBL] [Abstract][Full Text] [Related]
17. Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma.
Kajiura K; Masuda K; Naruto T; Kohmoto T; Watabnabe M; Tsuboi M; Takizawa H; Kondo K; Tangoku A; Imoto I
Oncotarget; 2017 Jan; 8(2):2890-2905. PubMed ID: 27926516
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
19. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
Yu J; Zhang H; Gu J; Lin S; Li J; Lu W; Wang Y; Zhu J
BMC Cancer; 2004 Sep; 4():65. PubMed ID: 15367334
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
